Yüklüyor......
Quality of Life in SMA Patients Under Treatment With Nusinersen
Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease...
Kaydedildi:
| Yayımlandı: | Front Neurol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8039289/ https://ncbi.nlm.nih.gov/pubmed/33854472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.626787 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|